Innovation Pharmaceuticals Inc (IPIX)

[Ro the Bull]

Just had this published on the NYT article in the comments a few minutes ago. A little more laymen than Astavakra's...

Interesting article, but this compound is at least 3-4 years behind another similar antibiotic that I haven't seen get the attention it deserves. The one I'm talking about just finished Phase 2B trials, was granted QIDP status under the GAIN act, and has had results that match or surpass Daptomycin's 7 day treatment either as a 3 day or as a 1 day course of treatment! Even better, testing indicates that bacterial resistance is extremely unlikely to develop. The company is Cellceutix, and one of their leading drugs in development, Brilacidin, also attacks the bacteria cell walls. Right now, it's going into Phase 3 for severe skin infections, such as MRSA and other resistant superbugs. What to know about it: attacks bacterial cell walls, single dose treatment has proven very effective with minimal drug-related side effects, works just like host defense proteins. It's part of a new class of antibiotics called Defensin Mimetics. Bacteria would need to evolve an entire new cell wall structure to develop immunity, similarly to Teixobactin, only this drug is a lot further along in the approval process! Also, Cellceutix has developed a room-temperature stable compound and are going to start a Phase 2 trial on Diabetic Foot Ulcers shortly! You can Google it and check out some of the company's press releases, including published results! This research is the tip of the iceberg!